Real-world use of tirzepatide among individuals without evidence of type 2 diabetes: Results from the Veradigm® database.

ABSTRACT:

Aims

To understand real-world tirzepatide use among individuals without type 2 diabetes (T2D) diagnoses in a US electronic health record (EHR) database.

Materials and methods

This retrospective, descriptive, cohort study used Veradigm's® Network EHR database linked with administrative claims. Adults (≥18 years) included had ≥1 tirzepatide prescription (index period: 13 May 2022-31 August 2023); continuous medical and pharmacy enrolment for ≥12 months pre-index; and no T2D diagnosis or baseline T2D medications except metformin (overall cohort). 'Anti-obesity medication (AOM)-eligible cohort' included individuals with body mass index (BMI) ≥30 or ≥27 kg/m² and ≥1 obesity-related complication (ORC) and ≥6 months of continuous post-index enrollment.

Results

The

SUBMITTER: Hunter Gibble T 

PROVIDER: S-EPMC12046461 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature